Compare Adobe Systems Inc (ADBE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs BIO-TECHNE Corp — how do they compare? Adobe Systems Inc trades at $263.79 (market cap $108.50B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Adobe Systems Inc is far larger — about 9.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | TECH | |
|---|---|---|
Market Cap | $108.50B | $11.24B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $72.29 |
52-Week Low | $193.41 | $43.31 |
Enterprise Value | $109.94B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $263.71, down 0.57% over 24 hours, with a bullish technical signal from moving averages. The company reported strong Q1 2026 EPS of $5.96, beating estimates, and maintains robust profitability with a net income margin of 28.69% and ROE of 62.95%. However, negative net cash flow of -$2.18B in 2025 and rising debt-to-asset ratio to 18.61% in 2024 highlight financial pressures. Recent news reflects mixed sentiment, with institutional buying amid AI competition concerns and a CEO transition.
Outlook: Adobe's consistent earnings beats and high margins support long-term growth, but AI-driven competitive threats and cash flow volatility pose risks. Analysts are broadly bullish with a 49.2% buy rating, though the consensus price target of $248.86 suggests limited upside from current levels. Investors should weigh solid fundamentals against sector headwinds.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
